0 524

Cited 18 times in

Therapeutic application of the CRISPR system: current issues and new prospects

DC Field Value Language
dc.contributor.author김형범-
dc.date.accessioned2019-10-28T01:43:00Z-
dc.date.available2019-10-28T01:43:00Z-
dc.date.issued2019-
dc.identifier.issn0340-6717-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/171305-
dc.description.abstractSince its discovery, the Clustered Regularly Interspaced Short Palindromic Repeat (the CRISPR) system has been increasingly applied to therapeutic genome editing. Employment of several viral and non-viral vectors has enabled efficient delivery of the CRISPR system to target cells or tissues. In addition, the CRISPR system is able to modulate the target gene's expression in various ways, such as mutagenesis, gene integration, epigenome regulation, chromosomal rearrangement, base editing and mRNA editing. However, there are still limitations hindering an ideal application of the system: inefficient delivery, dysregulation of the delivered gene, the immune response against the CRISPR system, the off-target effects or the unintended on-target mutations. In addition, there are recent discoveries that have not been yet applied to CRISPR-mediated therapeutic genome editing. Here, we review the overall principles related to the therapeutic application of the CRISPR system, along with new strategies for the further application and prospects to overcome the limitations.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish, German-
dc.publisherSpringer Verlag-
dc.relation.isPartOfHuman Genetics-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESH• CRISPR-Cas Systems*-
dc.subject.MESHEpigenomics/methods-
dc.subject.MESHGene Editing/methods*-
dc.subject.MESHGene Rearrangement-
dc.subject.MESHGene Transfer Techniques*-
dc.subject.MESHGenetic Therapy/methods-
dc.subject.MESHHumans-
dc.subject.MESHMutagenesis*-
dc.subject.MESHReproducibility of Results-
dc.titleTherapeutic application of the CRISPR system: current issues and new prospects-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pharmacology (약리학교실)-
dc.contributor.googleauthorMinyoung Lee-
dc.contributor.googleauthorHyongbum Kim-
dc.identifier.doi10.1007/s00439-019-02028-2-
dc.contributor.localIdA01148-
dc.relation.journalcodeJ01007-
dc.identifier.eissn1432-1203-
dc.identifier.pmid31115652-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs00439-019-02028-2-
dc.contributor.alternativeNameKim, Hyongbum-
dc.contributor.affiliatedAuthor김형범-
dc.citation.volume138-
dc.citation.number6-
dc.citation.startPage563-
dc.citation.endPage590-
dc.identifier.bibliographicCitationHuman Genetics, Vol.138(6) : 563-590, 2019-
dc.identifier.rimsid63372-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.